Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has shown a strong recovery in its main business, with significant revenue growth and improved profitability metrics. The revenue for the first half of 2025 reached 628 million yuan, a year-on-year increase of 17.91%, while the net profit attributable to the parent company was 73.41 million yuan, up 41.60% year-on-year [4][5] - The company is expected to continue its growth trajectory, with projected revenues of 1.31 billion yuan, 1.58 billion yuan, and 1.92 billion yuan for 2025, 2026, and 2027 respectively, reflecting growth rates of 19.27%, 20.30%, and 21.22% [3][5] Summary by Sections Financial Performance - In 2025, the company achieved a revenue of 1,091.86 million yuan, with a year-on-year growth rate of 30.94% [3] - The net profit attributable to the parent company for 2025 is forecasted to be 145.17 million yuan, representing a growth rate of 23.63% [3] - The gross margin for the first half of 2025 was 44.25%, an increase of 4.74 percentage points year-on-year [5] Business Segments - The drug molecule block business generated 520 million yuan in revenue for the first half of 2025, a growth of 14.35%, while the scientific reagent business saw revenue of 40.73 million yuan, up 87.60% [5] - The company is expanding its product lines and maintaining a stable market share in the drug molecule block sector, contributing to its revenue growth [5] Future Outlook - The company is focusing on new product development and expanding its overseas market presence, with overseas revenue for the first half of 2025 reaching approximately 363 million yuan, a growth of 21.33% [5] - The company is expected to benefit from its competitive advantages and continue to capture market share in the overseas market [5]